Patents by Inventor Arun P. Thottumkara

Arun P. Thottumkara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C26-linked rapamycin analogs as mTOR inhibitors
    Patent number: 11685749
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: June 27, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Christopher Michael Semko, Gang Wang, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Micah James Evans Gliedt, Jennifer Pitzen, Julie Chu-Li Lee, Walter Won, Arun P. Thottumkara, Adrian Liam Gill
  • RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20230093861
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: March 11, 2022
    Publication date: March 30, 2023
    Inventors: James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20230055672
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20220340596
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 30, 2020
    Publication date: October 27, 2022
    Inventors: Christopher Michael SEMKO, Gang WANG, G. Leslie BURNETT, James Bradley AGGEN, Gert KISS, James Joseph CREGG, Micah James Evans GLIEDT, Jennifer PITZEN, Julie Chu-Li LEE, Walter WON, Arun P. THOTTUMKARA, Adrian Liam GILL
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20210338824
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 28, 2020
    Publication date: November 4, 2021
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
    Patent number: 10980889
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: April 20, 2021
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20210094975
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 1, 2021
    Inventors: James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
  • Derivatives of amphotericin B
    Patent number: 10882883
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: January 5, 2021
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • DERIVATIVES OF AMPHOTERICIN B
    Publication number: 20200262858
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Application
    Filed: February 25, 2020
    Publication date: August 20, 2020
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of amphotericin B
    Patent number: 10597420
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 24, 2020
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20190336609
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2019
    Publication date: November 7, 2019
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • DERIVATIVES OF AMPHOTERICIN B
    Publication number: 20180273572
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Application
    Filed: April 9, 2018
    Publication date: September 27, 2018
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of amphotericin B
    Patent number: 9957290
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 1, 2018
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of Amphotericin B
    Publication number: 20160304548
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney
  • User- and eco-friendly hypervalent iodine reagent and method of synthesis
    Patent number: 6933405
    Abstract: The present invention is a user- and eco-friendly hypervalent iodine reagent (mIBX) capable of selectively oxidizing allylic and benzylic alcohols in water and other eco-friendly solvents and having generally the following structure: Allylic and benzylic alcohols are cleanly oxidized to the corresponding carbonyl compounds in water or water-THF mixtures, or other mixtures, using a water-soluble o-iodoxybenzoic acid derivative of the present invention.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: August 23, 2005
    Assignee: Board of Trustees of Western Illinois University
    Inventors: Thottumkara K. Vinod, Arun P. Thottumkara
  • User- and eco-friendly hypervalent iodine reagent and method of synthesis
    Publication number: 20040030187
    Abstract: The present invention is a user- and eco-friendly hypervalent iodine reagent (mIBX) capable of selectively oxidizing allylic and benzylic alcohols in water and other eco-friendly solvents and having generally the following structure: 1
    Type: Application
    Filed: July 31, 2003
    Publication date: February 12, 2004
    Inventors: Thottumkara K. Vinod, Arun P. Thottumkara